HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $19
HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $25 to $19.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F…
FDA Announced Clearance To Century Therapeutics’ Allogeneic Cell Therapy Candidate Study
Century Therapeutics, Inc. (NASDAQ: IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies.
Century Therapeutics Receives Study May Proceed Notification From FDA For CNTY-101
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA –
– First cell product candidate engineered with six